Mouse Model for Hepatic Artery Infusion via Celiac Catheterization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current animal models, such as New Zealand rabbits and Sprague-Dawley rats, are unsuitable for genetic-related research due to genetic instability, lack of genomic information, limited availability of antibodies and drugs, and longer maturation periods, making them less effective for hepatic artery infusion chemotherapy studies.

Innovation Solution

A method for preparing a mouse model via hepatic artery infusion by anesthetizing, surgically exposing the celiac artery, inserting a catheter, and administering drugs like oxaliplatin and 5-fluorouracil, with a simple and safe surgical procedure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If New Zealand rabbits or SD rats are used for HAIC-FO models, then drug administration is feasible, but genetic stability and experimental reproducibility deteriorate

Engineering Contradiction:

Improvedrug administration feasibilityVSAvoidgenetic stability

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the species parameter from rabbits/rats to mice, which have different anatomical characteristics. The common hepatic artery in mice can be accessed through the celiac trunk, enabling drug administration while maintaining genetic stability through inbred strains like C57BL/6

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a mouse model that copies the human hepatic artery infusion chemotherapy scenario. By establishing HAIC-FO models in mice with human-like tumor xenografts, it replicates the clinical treatment environment while using genetically stable animals

Inventive Principle:

Principle #26Copying

2Ease of operation

If New Zealand rabbits are used for HAIC-FO models, then drug administration is possible, but genomic information availability and research depth deteriorate

Engineering Contradiction:

Improvedrug administration capabilityVSAvoidgenomic information

Core Design Contradiction:

Ease of operationVSLoss of information

Solution Approach 1:

The patent changes the animal species parameter to mice, which have complete genome sequencing and extensive genomic resources. This enables access to comprehensive genomic information including gene expression databases, genetic maps, and molecular tools for mechanistic research

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If SD rats are used for HAIC-FO models, then hepatic artery catheterization is feasible, but maturation period and experimental time deteriorate

Engineering Contradiction:

Improvehepatic artery catheterizationVSAvoidmaturation period

Core Design Contradiction:

Ease of operationVSLoss of time

Solution Approach 1:

The patent changes the species parameter to mice, which reach sexual maturity at 6-8 weeks compared to 2-3 months for rats and 5-8 months for rabbits. This accelerates the experimental timeline while the common hepatic artery remains accessible for catheterization through the celiac trunk

Inventive Principle:

Principle #35Parameter changes

4Reliability

If inbred mice are used for HAIC-FO models, then genetic stability improves, but hepatic artery catheterization difficulty increases

Engineering Contradiction:

Improvegenetic stabilityVSAvoidhepatic artery catheterization

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent uses the celiac trunk as an intermediary structure to access the common hepatic artery. By catheterizing the celiac trunk first and then guiding the catheter into the common hepatic artery branch, it simplifies the procedure despite the small size of mouse hepatic vessels

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs preliminary localization of the common hepatic artery through anatomical landmarks and imaging guidance before catheter insertion. This preparatory step facilitates accurate catheter placement in the small hepatic artery of inbred mice

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250325359A1Method for preparing mouse model in which drugs are administrated via hepatic artery infusion and application thereof

Publication Date: 2025.10.23 SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

AI summary

A method for preparing a mouse model in which drugs are administrated via hepatic artery infusion includes fixing a mouse in a lateral position after being anesthetized, opening an abdominal cavity of the mouse layer by layer, freeing and exposing celiac artery, ligating two branches of the celiac artery except a common hepatic artery by making slipknots thereon by sterile sutures under an animal microscope, puncturing the celiac artery to make an opening by a 34G syringe, fixing a short segment of an L-shaped microcatheter in the sterile sutures, connecting a tail end of a long segment of the L-shaped microcatheter to a 1 ml syringe, injecting the drugs through the L-shaped microcatheter, removing the L-shaped microcatheter, pressing the opening of the celiac artery with gelatin sponge for hemostasis, removing all of the sterile sutures after above operations are completed.